Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights
Tectonic Therapeutic, Inc. (TECX)
Company Research
Source: GlobeNewswire
Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1’2025 or early Q2’2025First subject dosed with TX000045 (“TX45”) in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 (“TX2100”) selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027 WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”, or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced its financial results for the third quarter ending September 30, 2024, and provided an overview of recent business highlights. “Du
Show less
Read more
Impact Snapshot
Event Time:
TECX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TECX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TECX alerts
High impacting Tectonic Therapeutic, Inc. news events
Weekly update
A roundup of the hottest topics
TECX
News
- Tectonic Therapeutic (NASDAQ: TECX) is now covered by analysts at Raymond James. They set an "outperform" rating and a $65.00 price target on the stock.MarketBeat
- Tectonic Therapeutic Inc. Reports Q3 2024 Results [Yahoo! Finance]Yahoo! Finance
- Tectonic Therapeutic (NASDAQ: TECX) had its price target raised by analysts at Wells Fargo & Company from $55.00 to $79.00. They now have an "overweight" rating on the stock.MarketBeat
- Tectonic Therapeutic (NASDAQ: TECX) had its price target raised by analysts at Leerink Partners from $49.00 to $69.00. They now have an "outperform" rating on the stock.MarketBeat
- Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion ProteinGlobeNewswire
TECX
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form 10-Q
- 11/7/24 - Form 8-K
- TECX's page on the SEC website